stockrow
Saturday 31 October 2026
Export BMY’s income statement to Excel — free account
Bristol Myers Squibb Company
BMY Healthcare Drug Manufacturers General
Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 5.74%, EPS grew 153.1%, free cash flow fell 13.2% and total debt fell 12.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.
62.55
1.16
+1.89%
Follow BMY
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
15.19 | 15.59 | 17.04 | 12.69 |
P/S ratio |
1.91 | 2.28 | 2.55 | 2.39 | |
P/FCF ratio |
6.00 | 8.54 | 10.38 | 10.29 | |
P/Operating CF |
14.55 | 55.58 | 111.96 | 34.68 | |
P/B ratio |
4.94 | 5.93 | 6.15 | 5.27 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.59 | 2.99 | 3.25 | 3.04 | |
EV/EBITDA |
9.60 | 10.81 | 11.95 | 9.92 | |
EV/Operating CF |
7.48 | 10.18 | 11.84 | 11.71 | |
EV/FCF |
8.12 | 11.22 | 13.23 | 13.09 | |
Quick Ratio |
0.99 | 0.94 | 1.04 | 1.16 | |
Current Ratio |
1.27 | 1.26 | 1.42 | 1.53 | |
Net Debt/EBITDA |
7.87 | 14.06 | 8.86 | 6.85 | |
Debt/Assets |
50.55% | 50.10% | 51.41% | 49.20% | |
Debt/Equity |
2.63 | 2.44 | 2.21 | 1.93 | |
Asset Turnover |
0.50 | 0.53 | 0.54 | 0.54 | |
Operating CF/Net income |
2.87 | 1.82 | 0.41 | 1.02 | |
Capex/Depreciation |
(0.32) | (0.38) | (0.58) | (0.51) | |
Research and Development Expense of Revenue |
20.68% | 20.68% | 23.06% | 22.81% | |
Selling, General and Administrative Expense of Revenue |
14.64% | 17.45% | 14.07% | 14.08% | |
Intangible Assets out of Total Assets |
0.44 | 0.45 | 0.46 | 0.45 | |
Share Based Compensation of Revenue |
1.14% | 1.06% | 1.27% | 1.04% | |
Graham Net Nets |
(0.46) | (0.38) | (0.32) | (0.31) | |
Graham Number |
24.71 | 26.61 | 28.11 | 33.41 | |
Earnings Yield |
6.59% | 6.41% | 5.87% | 7.88% | |
Free Cash Flow Yield |
16.66% | 11.71% | 9.63% | 9.72% | |
Revenue per Share |
6.00 | 6.15 | 5.64 | 6.35 | |
Operating CF per Share |
3.10 | 0.97 | 0.54 | 1.66 | |
Capex per Share |
(0.16) | (0.18) | (0.17) | (0.15) | |
Free Cash Flow per Share |
2.94 | 0.79 | 0.37 | 1.51 | |
Cash per Share |
8.11 | 5.25 | 5.15 | 5.42 | |
Shareholders Equity per Share |
9.14 | 9.10 | 9.86 | 10.93 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
9.14 | 9.10 | 9.86 | 10.93 | |
Free Cash Flow |
5,991.00 | 1,604.00 | 757.00 | 3,088.00 | |
Working Capital |
7,494.00 | 5,973.00 | 8,050.00 | 9,920.00 | |
Capital Expenditures |
(320.00) | (370.00) | (347.00) | (305.00) | |
Net Current Asset Value |
(42,659.00) | (42,143.00) | (39,166.00) | (36,736.00) | |
EV/EBIT |
15.48 | 15.45 | 16.42 | 12.57 | |
Capex to Sales |
0.03 | 0.03 | 0.03 | 0.02 | |
Price to Operating Income |
11.43 | 11.76 | 12.88 | 9.88 | |
| Other line items | |||||
Average Receivables |
11,224.00 | 11,080.50 | 10,084.50 | 10,984.00 | |
Average Payables |
3,878.50 | 3,588.50 | 4,118.00 | 4,792.50 | |
Average Inventory |
3,045.00 | 2,623.50 | 2,711.00 | 2,737.00 | |
Average Assets |
95,279.50 | 91,320.50 | 89,451.50 | 91,155.00 | |
Average Common Equity |
17,899.50 | 17,446.50 | 18,774.50 | 19,904.00 |
Columns are period end dates